Eloralintide: A selective alternative targeting the amylin receptor for obesity management
-
-
REFERENCES
[1] Elmaleh-Sachs A., Schwartz J.L., Bramante C.T., et al. (2023). Obesity management in adults: A review. JAMA 330:2000−2015. DOI:10.1001/jama.2023.19897 [2] Walker C.S., Aitken J.F., Vazhoor Amarsingh G., et al. (2025). Amylin: Emergent therapeutic opportunities in overweight, obesity and diabetes mellitus. Nat. Rev. Endocrinol. 21:482−494. DOI:10.1038/s41574-025-01125-9 [3] Billings L.K., Hsia S., Bays H., et al. (2025). Eloralintide, a selective amylin receptor agonist for the treatment of obesity: A 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet 406:2631−2643. DOI:10.1016/S0140-6736(25)02155-5 [4] Lau D.C.W., Erichsen L., Francisco A.M., et al. (2021). Once-weekly cagrilintide for weight management in people with overweight and obesity: A multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet 398:2160−2172. DOI:10.1016/S0140-6736(21)01751-7 [5] Hay D.L., Chen S., Lutz T.A., et al. (2015). Amylin: Pharmacology, physiology, and clinical potential. Pharmacol. Rev. 67:564−600. DOI:10.1124/pr.115.010629 -
ABOUT THIS ARTICLE
Cite this article:
An Y., Dai Y. and Peng H. (2026). Eloralintide: A selective alternative targeting the amylin receptor for obesity management. The Innovation Medicine 4:100247. https://doi.org/10.59717/j.xinn-med.2026.100247
Welcome!
To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.
Export File
Citation
An Y., Dai Y. and Peng H. (2026). Eloralintide: A selective alternative targeting the amylin receptor for obesity management. The Innovation Medicine 4:100247. https://doi.org/10.59717/j.xinn-med.2026.100247
Format
Content
DownLoad:
-
Figure 1.
A Novel and Selective Amylin Receptor Agonist for Obesity Overview of a 48-week Phase 2 trial for eloralintide
